1.The safety and efficacy of Shuxuetong in treatment of paroxysmal atrial fibrillation in patients with chronic pulmonary heart disease
Jianling GU ; Si CHEN ; Kelei XU
Tianjin Medical Journal 2016;44(2):244-246
Objective To observe the clinical efficacy and safety of Shuxuetong in treatment of paroxysmal atrial fibril-lation in patients with chronic pulmonary heart disease. Methods A randomized single-blinded study was performed. A to-tal of 91 patients with paroxysmal atrial fibrillation and chronic pulmonary heart disease were randomly divided into treat-ment group (n=45) and control group (n=46). The treatment group was received Shuxuetong and clopidogrel treatment for 14 days. The control group was given routine treatment plus clopidogrel 75 mg orally. The average time of cardioversion of parox-ysmal atrial fibrillation was detected within 48 hours. The cardioversion rate of paroxysmal atrial fibrillation and the total effi-ciency were detected after14 days. The serum D-Dimer was detected before and 14 days after treatment . Liver and kidney function and adverse drug reactions were also detected. Results There was no significant difference in average time of car-dioversion of paroxysmal atrial fibrillation in 48 h between two groups (h:12.62±2.32 vs 13.32±2.25,t=1.461). The cardiover-sion rates were 86.67%(39/45) and 82.22%(37/45) at 48 h and 14 d in treatment group, which were significantly higher than those of control group [69.56%(32/46) and 60.87(28/46)]. The D-Dimer at 14 d after treatment was significantly lower in treatment group [(2.05±0.34)mg/L] than before treatment[(2.61±0.27)mg/L], also than that of control group[(2.53±0.31)mg/L]. There were no abnormal liver and kidney function and no adverse reactions between two groups. Conclusion Shuxuetong can significantly prevent the recurrence of paroxysmal atrial fibrillation in patients with chronic pulmonary heart disease, and help to reduce the risk of thromboembolism. It is safe and effective.
2.Strategies for the development of medical research institutions in Shanghai
Hanwen MAO ; Jianling REN ; Qinlong GU ; Weilin JANG ; Libo JIANG ; Wenyi XU ; Jinrong SUN
Chinese Journal of Medical Science Research Management 2010;23(4):217-219,249
Medical research institutions in Shanghai have been developing in at a slow pace because of problems such as out of date institution structures, unreasonable resource allocation and distribution,shortage of research resources, insufficient creativity, and unfocused effort and investment. Hence reform is the only way out. This research discussed the possible strategies for development and proposed some suggestions on the institution categorization, structure change, allocation of resource and overall arrangement.
3.Metabolic Disease Management Guideline for National Metabolic Management Center(2nd edition)
Weiqing WANG ; Yufan WANG ; Guixia WANG ; Guang NING ; Dalong ZHU ; Ping LIU ; Libin LIU ; Jianmin LIU ; Zhaoli YAN ; Xulei TANG ; Bangqun JI ; Sunjie YAN ; Heng SU ; Jianling DU ; Sheli LI ; Li LI ; Shengli WU ; Jinsong KUANG ; Yubo SHA ; Ping ZHANG ; Yifei ZHANG ; Lei CHEN ; Zunhai ZHOU ; Chao ZHENG ; Qidong ZHENG ; Zhongyan SHAN ; Dong ZHAO ; Zhigang ZHAO ; Ling HU ; Tingyu KE ; Yu SHI ; Yingfen QIN ; Mingjun GU ; Xuejiang GU ; Fengmei XU ; Zuhua GAO ; Qijuan DONG ; Yi SHU ; Yuancheng DAI
Chinese Journal of Endocrinology and Metabolism 2023;39(6):538-554
The latest epidemiological data suggests that the situation of adult diabetes in China is severe, and metabolic diseases have become significant chronic illnesses that have a serious impact on public health and social development. After more than six years of practice, the National Metabolic Management Center(MMC) has developed distinctive approaches to manage metabolic patients and has achieved a series of positive outcomes, continuously advancing the standardized diagnosis and treatment model. In order to further improve the efficiency, based on the first edition, the second edition guideline was composed by incorporating experience of the past six years in conjunction with the latest international and domestic guidelines.